Technology
Health
Biotechnology

Fortress Biotech

$1.80
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.01 (-0.55%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell FBIO and other stocks, options, ETFs, and crypto commission-free!

About

Fortress Biotech, Inc. engages in the development and commercialization of novel pharmaceutical and biotechnology products. It operates through the following segments: Dermatology Product Sales, Pharmaceutical and Biotechnology Product Development, and National. Read More The National segment consists of National Holdings Corporation, an independent brokerage company. The company was founded on June 28, 2006 in and is headquartered in New York, NY.

Employees
88
Headquarters
New York, New York
Founded
2006
Market Cap
101.69M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
325.54K
High Today
$1.86
Low Today
$1.77
Open Price
$1.81
Volume
67.38K
52 Week High
$5.22
52 Week Low
$0.49

Collections

Technology
Health
Biotechnology
Pharmaceutical
US
North America

News

Guru FocusMar 14

Fortress Biotech to Present at the 31st Annual ROTH Conference

NEW YORK, March 14, 2019 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. ( FBIO) (“Fortress”), an innovative biopharmaceutical company focused on identifying, in-licensing and developing high-potential clinical-stage assets, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will present a company overview at the 31st Annual ROTH Conference. The presentation will take place on Tuesday, March 19, 2019, at 3:00 p.m. PDT at The Ritz-Carlton, Laguna Niguel in Dana Point...

91
Yahoo FinanceMar 14

All You Need to Know About Fortress Biotech (FBIO) Rating Upgrade to Strong Buy

Fortress Biotech (FBIO) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects.

111
Simply Wall StMar 4

Those Who Purchased Fortress Biotech Shares A Year Ago Have A 53% Loss To Show For It

It is a pleasure to report that the Fortress Biotech, Inc. (NASDAQ:FBIO) is up 65% in the last quarter. But that doesn’t change the fact that the returns over the last year have been disappointing. During that time the share price has sank like a stone, descending 53%. It’s not that amazing to see a bounce after a drop like that. Arguably, the fall was overdone. See our latest analysis for Fortress Biotech Fortress Biotech isn’t a profitable company, so it is unlikely we’ll see a strong correlation betwee...

380

Earnings

-$0.67
-$0.52
-$0.37
-$0.22
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.58 per share
Actual
Available Mar 18, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.